



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	143.47
Trade Time:	4:00 PM ET Sep 19, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	96.93 - 144.00
Volume	2,001

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 8, 2017*
[Data Presented at ESMO 2017 Further Evaluate Role of ABRAXANE® for Patients with Historically Challenging Cancers](#)
- Sep 7, 2017*
[Celgene Provides Update on the Fusion™ Clinical Program](#)
- Aug 24, 2017*
[Celgene Corporation to Webcast at Upcoming Investor Conferences](#)
- Aug 1, 2017*
[FDA Grants Approval of IDHIFA®@, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)
- Jul 28, 2017*
[Celgene Corporation to Webcast at Upcoming Investor Conference](#)

Upcoming Events [\[View all \]](#)

- Sep 26, 2017 9:45 AM ET*
[Cantor Fitzgerald 3rd Annual Healthcare Conference](#)
- Events** [\[View all \]](#)
- Financials** [\[View all \]](#)
- Feb 10, 2017*
[Annual Report \(10-K\)](#)
- Apr 27, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Jul 27, 2017*
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017*
[Quarterly Report \(10-Q\)](#)
- Oct 27, 2016*
[Quarterly Report \(10-Q\)](#)